Merck & Co Inc

We think the payouts on these undervalued names are sustainable.

It already had a solid lineup even before news of its potential COVID-19 treatment.

Our analysts discuss where they see value in their sectors today.

These narrow- and wide-moat names have suffered losses during the past year and look cheap to us.

We see some opportunity for investment, especially in Merck.

We turn to the Morningstar US Dividend Growth Index for stock ideas.

We plan to maintain our fair value estimate for the wide-moat firm, which offered solid 2020 guidance.

Big names in pharma and biotech also report earnings, and labor data to come on Friday.

These high-quality names were recently added to the Morningstar Wide Moat Focus Index.

Recent results from some of the most undervalued large drugmakers we cover.

These names were recently added to the Morningstar Wide Moat Focus Index.

These stocks all experienced significant fair-value increases in June--and one enjoyed a moat boost, too.

We think the market underappreciates some large pharma and biotech names.

A broad array of oncology and autoimmune programs gives the company a larger margin of error.

The continued strong data in multiple cancers reinforces the strength of Keytruda across multiple indications.

It's a full week of earnings, with Apple, Amazon, Facebook, and Microsoft all trading in 4-star range ahead of their reports.

We review the adds and drops from the latest reconstitution as well as the index's cheapest names today.

We think the deal is strategically and financially positive.

Large-cap growth and large-cap value strategies maintain gains above index, market is undervalued.

The Morningstar Wide Moat Focus Index has added several semiconductor stocks and asset managers, among others, to its roster.